Home > Products > Featured products

PF-04971729 (Ertugliflozin)

  Cat. No.:  DC3108   Featured
Chemical Structure
1210344-57-2
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 1210344-57-2
Chemical Name: PF04971729,PF 04971729 (Ertugliflozin)
Synonyms: PF04971729,PF 04971729 (Ertugliflozin)
SMILES: C1=CC([C@@]23O[C@@](CO)(CO2)[C@H](O)[C@@H](O)[C@@H]3O)=CC(CC2=CC=C(OCC)C=C2)=C1Cl
Formula: C22H25ClO7
M.Wt: 436.9
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[1]. A drug for the treatment of type 2 diabetes mellitus[2].
In Vivo: Ertugliflozin (PF-04971729) reveals a concentration-dependent glucosuria after oral administration to rats[3].
In Vitro: Ertugliflozin (PF-04971729) demonstrates >2000-fold selectivity for SGLT2 inhibition (relative to SGLT1) in vitro[3].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC3108 PF-04971729 (Ertugliflozin) PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus.
DC7921 Sotagliflozin (LX-4211) LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
DC6904 DAPAGLIFLOZIN Dapagliflozin, also known as BMS-512148, is a drug used to treat type 2 diabetes approved in 2012 by FDA. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter mechanism causes blood glucose to be eliminated through the urine. In clinical trials, dapagliflozin lowered HbA1c by 0.6 versus placebo percentage points when added to metformin.
DC3111 Canagliflozin Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.
DC8186 Bexagliflozin3 Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia